市場調査レポート

商品コード

CAR-T細胞療法市場 - 標的適応症別・標的抗原別・主要企業別・主要地域別：将来予測 (2022年～2035年)

CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2022-2035

出版日: 2023年08月01日 | 発行: Roots Analysis

| ページ情報: 英文 700 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,799 751,187円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,095,553円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,659,061円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,817,383円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.53円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界のCAR-T細胞療法の市場について分析し、製品の概要や現在の治験・市場動向、関連特許の出願・承認の動き、主な投資・資金調達・助成金の動向、事業提携・協力の動き、セグメント別・地域別の市場動向の見通し (2022年～2035年)、主要企業のプロファイルや製品ポートフォリオ、業界関係者の見解などを調査しております。

分析概要
Kymriah / Tisagenlecleucel / CTL019 (Novartis)
Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
TBI-1501 / CD19 CAR-T細胞療法 (Takara Bio)
AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
AUTO3 / CD19/22 CAR-T (Autolus)

第9章事業提携・協力

分析概要
事業提携モデル
CAR-T細胞療法：事業提携・協力

第10章資金提供・投資の分析

分析概要
資金の種類
CAR-T細胞療法：資金提供・投資の分析

第11章特許分析

分析概要
分析範囲・手法
CAR-T細胞療法：特許分析

第12章ケーススタディ：細胞療法の製造

分析概要
細胞療法の製造：概要
細胞療法の製造モデル
細胞療法の製造プロセスのスケーラビリティ
細胞療法メーカーの種類
細胞療法の製造に関連する主な課題
細胞療法の製造に関する重要な考慮事項
細胞療法の製造プロセスの自動化
細胞療法の製造サプライチェーン
内製能力を持つ企業と受託メーカーの比較
規制状況
将来の展望

第13章費用・価格分析

分析概要
細胞・遺伝子治療の高額化の要因
T細胞免疫療法の価格モデル
T細胞免疫療法の償還関連の考慮事項

第14章市場予測と機会分析

分析概要
範囲と制限
主な仮定と予測手法
世界のCAR-T細胞療法市場 (2022年～2035年)

第15章プロモーション分析

分析概要
プロモーションキャンペーンに使用されるチャネル
製品Webサイトの分析：サマリー
患者サポートサービスと情報ダウンロード：概要
Kymriah (R)：プロモーション分析
Yescarta (R)：プロモーション分析
Tecartus (R)：プロモーション分析
Breyanzi (R)：プロモーション分析
Abecma (R)：プロモーション分析
Carvykti (R)：プロモーション分析

第16章企業プロファイル

分析概要
Alaunos Therapeutics
Autolus
Bluebird Bio
Bristol Myers Squibb
Carsgen Therapeutics
Cellectis
Cellular Biomedicine Group
Gilead Sciences
Innovative Cellular Therapeutics
Kuur Therapeutics
Noile-Immune Biotech
Novartis
Shanghai GeneChem
Sinobioway Cell Therapy
Takara Bio
Wellington Zhaotai Therapies

第17章結論

第18章企業役員の見解

分析概要
Glycostem Therapeutics
Gracell Biotechnologies
TxCell
Kite Pharma
Celyad
Waisman Biomanufacturing
Theravectys
Changhai Hospital
University of Colorado

第19章付録1：表形式のデータ

第20章付録2：企業・組織の一覧

図表

LIST OF TABLES

Table 4.1 Biosensors in Drug Discovery: List of Companies
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 4.1 CAR-T Cell Therapies: Clinical Pipeline
Table 4.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 4.4 List of CAR-T cells Developers
Table 5.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 8.1 CAR-T Cell Therapies: List of Therapies Profiled
Table 8.2 Therapy Profile: Kymriah® (Novartis)
Table 8.3 Kymriah: Clinical Trial Information
Table 8.4 Kymriah: Clinical Trial Endpoints
Table 8.5 Kymriah: Clinical Trial Results
Table 8.6 Therapy Profile: Yescarta (Gilead Sciences)
Table 8.7 Yescarta: Clinical Trial Information
Table 8.8 Yescarta: Clinical Trial Endpoints
Table 8.9 Yescarta: Clinical Trial Results
Table 8.10 Therapy Profile: Tecartus (Gilead Sciences)
Table 8.11 Tecartus: Clinical Trial Information
Table 8.12 Tecartus: Clinical Trial Endpoints
Table 8.13 Tecartus: Clinical Trial Results
Table 8.14 Therapy Profile: Breyanzi (Bristol Myers Squibb)
Table 8.15 Breyanzi: Clinical Trial Information
Table 8.16 Breyanzi: Clinical Trial Endpoints
Table 8.17 Breyanzi: Clinical Trial Results
Table 8.18 Therapy Profile: Abecma (Bristol Myers Squibb)
Table 8.19 Abecma: Clinical Trial Information
Table 8.20 Abecma: Clinical Trial Endpoints
Table 8.21 Abecma: Clinical Trial Results
Table 8.22 Therapy Profile: Carvykti (Janssen)
Table 8.23 Carvykti: Clinical Trial Information
Table 8.24 Carvykti: Clinical Trial Endpoints
Table 8.25 Carvykti: Clinical Trial Results
Table 8.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 8.27 Carteyva: Clinical Trial Information
Table 8.28 Carteyva: Clinical Trial Endpoints
Table 8.29 Carteyva: Clinical Trial Results
Table 8.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 8.31 TBI-1501: Clinical Trial Information
Table 8.32 TBI-1501: Clinical Trial Endpoints
Table 8.33 Therapy Profile: AUTO1 (Autolus)
Table 8.34 AUTO1: Clinical Trial Information
Table 8.35 AUTO1: Clinical Trial Endpoints
Table 8.36 AUTO1: Clinical Trial Results
Table 8.37 Therapy Profile: AUTO3 (Autolus)
Table 8.38 AUTO3: Clinical Trial Information
Table 8.39 AUTO3: Clinical Trial Endpoints
Table 8.40 AUTO3: Clinical Trial Results
Table 9.1 CAR-T Cell Therapies: List of Partnerships and Collaborations, 2005-2022
Table 10.1 CAR-T Cell Therapies: Funding and Investments, 2000-2022
Table 10.2 CAR-T Cell Therapies: Summary of Investments
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 CAR-T Cell Therapies: Expert Opinions on Pricing
Table 13.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 14.1 CAR-T Cell Therapies: List of Forecasted Molecules
Table 14.2 Kymriah (Novartis): Net Present Value (USD Million)
Table 14.3 Kymriah (Novartis): Value Creation Analysis (USD Million)
Table 14.4 Yescarta (Gilead Sciences): Net Present Value (USD Million)
Table 14.5 Yescarta (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.6 Tecartus: (Gilead Sciences): Net Present Value (USD Million)
Table 14.7 Tecartus: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.8 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 14.11 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 14.12 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.13 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.14 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 14.15 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 14.16 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.17 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.18 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 14.19 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 14.20 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.21 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.22 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.23 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.24 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 14.25 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 14.26 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 14.27 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 14.28 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 14.29 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 14.30 TAK-007 (Takeda): Net Present Value (USD Million)
Table 14.32 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 14.33 AUTO1 (Autolus): Net Present Value (USD Million)
Table 14.34 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 14.35 AUTO3 (Autolus): Net Present Value (USD Million)
Table 14.36 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 14.37 CD19 CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 14.38 CD19 CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 18.39 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.40 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.41 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.42 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.43 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 14.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 14.45 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 14.46 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 14.47 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 14.48 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.49 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 14.50 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 14.51 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.53 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 14.54 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 14.55 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.57 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 14.58 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 14.59 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 14.60 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.61 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.63 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 14.64 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 14.65 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.66 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.67 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.69 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 14.70 CT053 (CARsgen Therapeutics): Value Creation Analysis (USD Million)
Table 14.71 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 14.73 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.75 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.76 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.77 WU CART 007 (WUGEN): Net Present Value (USD Million)
Table 14.78 WU CART 007 (WUGEN): Value Creation Analysis (USD Million)
Table 14.79 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 14.80 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 15.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 15.2 Kymriah: Drug Overview
Table 15.3 Yescarta: Drug Overview
Table 15.4 Tecartus: Drug Overview
Table 15.5 Breyanzi: Drug Overview
Table 15.6 Abecma: Drug Overview
Table 15.7 Carvykti: Drug Overview
Table 16.1 Leading CAR-T Cell Therapy Developers
Table 16.2 Autolus: Company Profile
Table 16.3 bluebird bio: Company Profile
Table 16.4 Bristol Myers Squibb: Company Profile
Table 16.5 CARsgen Therapeutics: Company Profile
Table 16.6 Cellectis: Company Profile
Table 16.7 Cellular Biomedicine Group: Company Profile
Table 16.8 Gilead Sciences: Company Profile
Table 16.9 Innovative Cellular Therapeutics: Company Profile
Table 16.10 Kuur Therapeutics: Company Profile
Table 16.11 Noile-Immune Biotech: Company Profile
Table 16.12 Novartis: Company Profile
Table 16.13 Shanghai Genechem: Company Profile
Table 16.14 Sinobioway Cell Therapy: Company Profile
Table 16.15 Takara Bio: Company Profile
Table 16.16 Wellington Zhaotai Therapies: Company Profile
Table 19.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 19.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 19.3 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
Table 19.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Table 19.5 CAR-T Cell Therapies: Distribution by Key Target Indications
Table 19.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 19.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cell
Table 19.9 CAR-T Cell Therapies: Distribution by Route of Administration
Table 19.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Table 19.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 19.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 19.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 19.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 19.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 19.18 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 19.19 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Table 19.20 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.21 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 19.22 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.23 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Table 19.24 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.25 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 19.26 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.27 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.30 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 19.31 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 19.32 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 19.33 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 19.34 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 19.35 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 19.36 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Table 19.37 CAR-T Cell Therapies: Geographical Distribution of KOLs
Table 19.38 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Table 19.39 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 19.40 Kymriah: Estimated Sales Revenues
Table 19.41 Yescarta: Estimated Sales Revenues
Table 19.42 Tecartus: Estimated Sales Revenues
Table 19.43 Breyanzi: Estimated Sales Revenues
Table 19.44 Abecma: Estimated Sales Revenues
Table 19.45 Carvykti: Estimated Sales Revenues
Table 19.46 Carteyva: Estimated Sales Revenues
Table 19.47 AUTO1: Estimated Sales Revenues
Table 19.48 AUTO3: Estimated Sales Revenues
Table 19.49 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 19.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.51 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 19.52 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 19.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.54 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 19.55 Most Popular Products: Distribution by Number of Partnerships
Table 19.56 Most Active Industry Players: Distribution by Number of Partnerships
Table 19.57 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 19.58 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 19.59 Partnerships and Collaborations: Distribution of International and Local Agreements
Table 19.60 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 19.61 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 19.62 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.63 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.64 Funding and Investments: Distribution by Type of Investors
Table 19.65 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 19.66 Most Active Players: Distribution by Number of Instances
Table 19.67 Most Active Players: Distribution by Amount Invested (USD Million)
Table 19.68 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 19.69 Most Active Investors: Distribution by Number of Funding Instances
Table 19.70 Patent Analysis: Distribution by Type of Patent
Table 19.71 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 19.72 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 19.73 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 19.74 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 19.75 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 19.76 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Table 19.77 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Table 19.78 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Table 19.79 Leading Industry Players: Distribution by Number of Patents
Table 19.80 Leading Non-Industry Players: Distribution by Number of Patents
Table 19.81 Leading Patent Assignees: Distribution by Number of Patents
Table 19.82 Patent Analysis: Distribution by Patent Age
Table 19.83 CAR-T Therapies: Patent Valuation Analysis

LIST OF FIGURES

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 4.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 4.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 4.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR-T Cell Therapies: Distribution by Key Target Indication
Figure 4.6 CAR-T Cell Therapies: Distribution by Key Target Antigen
Figure 4.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 4.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 4.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Figure 4.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 4.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 5.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 5.3 CAR-Construction: Distribution by Generation of CAR
Figure 5.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 5.5 CAR-Construction: Distribution by Type of Virus Used
Figure 5.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 5.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution of trials by Trial Registration Year, Pre-2013-2022
Figure 6.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 6.6 Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Figure 6.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 6.8 Clinical Trial Analysis: Distribution by Target Patient
Figure 6.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.10 Clinical Trial Analysis: Distribution by Study Design
Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
Figure 6.12 Most Active Players: Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Key Focus Areas
Figure 6.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 6.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 6.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 6.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.1 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 7.2 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 7.3 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Figure 7.4 CAR-T Cell Therapies: Geographical Distribution of KOLs
Figure 7.5 CAR-T Cell Therapies Scatter Plot: KOL Activenes s versus KOL Strength
Figure 7.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 7.7 Most Prominent KOLs: Distribution by RA Score
Figure 7.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 7.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 8.1 Kymriah: Estimated Sales Revenues
Figure 8.2 Yescarta: Estimated Sales Revenues
Figure 8.3 Tecartus: Estimated Sales Revenues
Figure 8.4 Breyanzi: Estimated Sales Revenues
Figure 8.5 Abecma: Estimated Sales Revenues
Figure 8.6 Carvykti: Estimated Sales Revenues
Figure 8.7 Carteyva: Estimated Sales Revenues
Figure 8.8 AUTO1: Estimated Sales Revenues
Figure 8.9 AUTO3: Estimated Sales Revenues
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 9.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 9.7 Most Popular Products: Distribution by Number of Partnerships
Figure 9.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 9.11 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 10.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 10.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution by Types of Investors
Figure 10.6 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.7 Most Active Players: Distribution by Number of Instances
Figure 10.8 Most Active Players: Distribution by Amount Invested (USD Million
Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 11.3 Patent Analysis: Cumulative Distribution Patent Application Year
Figure 11.4 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 11.5 Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 11.6 Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 11.7 Patent Analysis: Distribution by Geography
Figure 11.8 Patent Analysis: Distribution by Type of Player
Figure 11.9 Patent Analysis: Distribution by CPC Symbols
Figure 11.10 Patent Analysis: Key Focus Area
Figure 11.11 Leading Industry Players: Distribution by Number of Patents
Figure 11.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 11.15 Patent Analysis: Distribution by Patent Age
Figure 11.14 CAR-T Cell Therapies: Patent Valuation Analysis
Figure 12.1 Steps for Manufacturing Cell Therapies
Figure 12.2 Centralized Manufacturing: Process Model
Figure 12.3 Decentralized Manufacturing: Process Model
Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5 Cell Therapy: Challenges and Drivers
Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 14.1 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Figure 14.2 CAR-T Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Figure 14.3 CAR-T Cell Therapies Market: Distribution by Target Antigen(s), 2025 and 2035 (USD Billion)
Figure 14.4 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 14.5 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 14.6 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 14.7 Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.8 Tecartus (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 14.11 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.12 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.13 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.14 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.15 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.16 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.17 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 14.18 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 14.19 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.20 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 14.21 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.22 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.23 CD19 CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 14.24 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2035 (USD Million)
Figure 14.25 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.26 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.27 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 14.28 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 14.29 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 14.30 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.31 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.32 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.33 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.34 IC9-CAR19 T Cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 14.35 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.36 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.37 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.38 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.39 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.40 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 14.41 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.42 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.43 WU CART 007 (WUGEN) Sales Forecast, till 2035 (USD Million)
Figure 14.44 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 15.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 15.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 15.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 15.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 15.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 15.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 15.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 15.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 15.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 15.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 15.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 15.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 15.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 15.17 Product Website Analysis: Abecma, Messages for Patients
Figure 15.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 15.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 15.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 15.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 17.1 Concluding Remarks: Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Key Opinion Leaders
Figure 17.4 Concluding Remarks: Partnerships & Collaborations
Figure 17.5 Concluding Remarks: Funding and Investment Analysis
Figure 17.6 Concluding Remarks: Patent Analysis
Figure 17.7 Concluding Remarks: Market Forecast

Product Code: RA100389

INTRODUCTION

The cancer is the one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems. Even though a number of treatment options are available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is still difficult to achieve. Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T cell therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.

At present, more than 5 CAR-T therapies have been approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). In fact, more than 170 companies are engaged in the development of over 970 early and late-stage CAR-T cell therapies, worldwide. Moreover, several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,500 patents related to CAR-T cell therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, more than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund product development initiatives, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR-T cell therapy market is likely to witness significant growth in the foreseen future.

SCOPE OF THE REPORT

The "CAR-T Cell Therapy Market (4^th Edition) by Target Indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Global Forecast 2022-2035" report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

A detailed assessment of the current market landscape of CAR-T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).

An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies, considering them to be KOLs, who are actively involved in R&D of CAR-T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.

An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.

An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.

An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell based immunotherapy that is likely to be marketed in the coming years.

A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).

Elaborate profiles of the several leading players in the domain of CAR-T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of CAR-T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR-T cell therapy market, wherein opportunity has been segmented across [A] target indications (non-hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma), [B] target antigens (CD19, BCMA, CD19 / CD22 and others), Key Players and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)

Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)

Miguel Forte (Chief Operating Officer, TxCell)

Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)

Vincent Brichard (Vice President, Immuno-Oncology, Celyad)

Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)

Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)

Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in this domain (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

KEY QUESTIONS ANSWERED

What are the prevalent R&D trends related to CAR-T cell therapies?

Which different types of clinical conditions can be treated using CAR-T cell therapies?

Who are the leading industry and non-industry players in this market?

In which geographies, extensive research on CAR-T cell therapy is being conducted?

What kind of partnership models are commonly adopted by industry stakeholders?

Who are the key investors in the CAR-T cell immunotherapy domain?

Who are the key opinion leaders / experts from renowned academic and research institutes which can help drive product development efforts in this domain?

How is the intellectual property landscape for global CAR-T cell therapies likely to evolve in the foreseen future?

Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture CAR-T cell therapies?

What are the key factors that are likely to influence the evolution of the CAR-T cell immunotherapies market?

How is the current and future market opportunity likely to be distributed across key market segments?

What are the key promotional strategies used by companies having marketed products?

CHAPTER OUTLINES

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T cell therapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of CAR-T cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of CAR-T cell-based therapies and the challenges associated with such therapies.

Chapter 4 includes detailed assessment of the current market landscape of more than 970 CAR-T cell therapies that are currently approved or are in different stages of the development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19/22, EGFR, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).

Chapter 5 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

Chapter 6 presents a detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

Chapter 7 presents an analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies, considering them to be KOLs, who are actively involved in R&D of CAR-T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 10 provides details on the various investments and grants that have been awarded to several stakeholders focused on the development of CAR-T cell therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 11 provides an in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 12 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. Additionally, it includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 13 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their CAR-T cell-based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 14 features an elaborate discussion on the future commercial opportunity offered by CAR-T cell therapies. It provides a comprehensive market forecast analysis for CAR-T cell products that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indications (Non-hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), [B] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, and others) and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).

Chapter 15 highlights the key promotional strategies that are being implemented by the developers of the approved CAR-T Cell therapies (Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™) and TCR-based therapies (Kimmtrak®). The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 16 includes brief company profiles of the leading players in the domain of CAR-T cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 17 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics, Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

1. PREFACE

1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapy
- 3.5.1. By Mechanism of Action
  - 3.5.1.1. Active Immunotherapy
  - 3.5.1.2. Passive Immunotherapy
- 3.5.2. By Type of Target
- 3.5.3. By Approach
  - 3.5.3.1. Activation and Suppression Immunotherapy
- 3.5.4. By Product Class
  - 3.5.4.1. Monoclonal Antibodies
  - 3.5.4.2. Bispecific Antibodies
  - 3.5.4.3. Cytokines
  - 3.5.4.4. Oncolytic Virus Therapy
  - 3.5.4.5. Therapeutic Cancer Vaccines
  - 3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
- 3.6.1. Historical Evolution
- 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
- 3.6.3. Strategies Employed for the Redirection of T-Cells
- 3.6.4. Manufacturing of Engineered T-Cells
- 3.6.5. T-Cell Transduction and Transfection Methods
  - 3.6.5.1. Retroviral Vectors
  - 3.6.5.2. Lentiviral Vectors
  - 3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
- 3.7.1. Development History
- 3.7.2. Anatomical Layout of CAR
  - 3.7.2.1. Ectodomain
  - 3.7.2.2. Transmembrane (TM) Domain
  - 3.7.2.3. Endodomain
- 3.7.3. Development of CAR-T Cells
- 3.7.4. Universal CAR-T Cells
- 3.7.5. Route of Administration
- 3.7.6. Case Study on CD19 CAR-T Cell Therapies
  - 3.7.6.1. Other Important Biological Targets for CAR Development
- 3.7.7. Challenges Associated with CAR-T Cell Therapies
  - 3.7.7.1. Competitive Risks
  - 3.7.7.2. Clinical Risks
  - 3.7.7.3. Regulatory Risks
  - 3.7.7.4. Commercial Risks
3.8. Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE

4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
- 4.2.1. Analysis by Type of Developer
- 4.2.2. Analysis by Phase of Development
- 4.2.3. Analysis by Therapeutic Area
- 4.2.4. Analysis by Phase of Development and Therapeutic Area
- 4.2.5. Analysis by Key Target Indication
- 4.2.6. Analysis by Key Target Antigen
- 4.2.7. Analysis by Source of T-Cells
- 4.2.8. Analysis by Phase of Development and Source of T-Cells
- 4.2.9. Analysis by Route of Administration
- 4.2.10. Analysis by Dosing Frequency
- 4.2.11. Analysis by Target Patient Segment
- 4.2.12. Analysis by Type of Therapy
- 4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
- 4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies
4.3. CAR-T Cell Therapies: Overall Developer Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters

5. KEY INSIGHTS

5.1. Chapter Overview
5.2. CAR-T Cell Therapies: Competitive Analysis of Popular Target Antigens
- 5.2.1. Popular Targets Related to Hematological Malignancies
- 5.2.2. Popular Targets Related to Solid Tumors
5.3. T-Cell Immunotherapies: CAR Construct Analysis
- 5.3.1. Analysis by Generation of CAR
- 5.3.2. Analysis by Type of scFv Antibody
- 5.3.3. Analysis by Type of Virus Used
- 5.3.4. Analysis by Type of Gene Transfer Method Used
- 5.3.5. Analysis by Type of Co-Stimulatory Domain

6. CLINICAL TRIAL ANALYSIS

6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CAR-T Cell Therapies: Clinical Trial Analysis
- 6.3.1. Analysis of Trials by Trial Registration Year
- 6.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
- 6.3.3. Analysis by Trial Status
- 6.3.4. Analysis by Trial Registration Year and Trial Status
- 6.3.5. Analysis by Trial Phase
- 6.3.6. Analysis of Enrolled Patient Population by Trial Phase
- 6.3.7. Analysis by Target Patient Segment
- 6.3.8. Analysis by Type of Sponsor / Collaborator
- 6.3.9. Analysis by Study Design
- 6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 6.3.12. Analysis by Key Focus Areas
- 6.3.13. Analysis of Trials by Geography
- 6.3.14. Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS

7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. CAR-T Cell Therapies: Key Opinion Leaders
- 7.4.1. Analysis by Type of Organization
- 7.4.2. Analysis by Affiliated Organization
- 7.4.3. Analysis by Qualification
- 7.4.4. Analysis by Geographical Location of KOLs
- 7.4.5. KOL Activeness versus KOL Strength
- 7.4.6. Most Prominent KOLs: Analysis by RA score
- 7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. CAR-T CELL THERAPY PROFILES

8.1. Chapter Overview
8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
- 8.2.1. Therapy Overview
- 8.2.2. Clinical Trial Information
- 8.2.3. Clinical Trial Endpoints
- 8.2.4. Clinical Trial Results
- 8.2.5. Estimated Sales Revenues
8.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
- 8.3.1. Therapy Overview
- 8.3.2. Clinical Trial Information
- 8.3.3. Clinical Trial Endpoints
- 8.3.4. Clinical Trial Results
- 8.3.5. Estimated Sales Revenues
8.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
- 8.4.1. Therapy Overview
- 8.4.2. Clinical Trial Information
- 8.4.3. Clinical Trial Endpoints
- 8.4.4. Clinical Trial Results
- 8.4.5. Estimated Sales Revenues
8.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
- 8.5.1. Therapy Overview
- 8.5.2. Clinical Trial Information
- 8.5.3. Clinical Trial Endpoints
- 8.5.4. Clinical Trial Results
- 8.5.5. Estimated Sales Revenues
8.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
- 8.6.1. Therapy Overview
- 8.6.2. Clinical Trial Information
- 8.6.3. Clinical Trial Endpoints
- 8.6.4. Clinical Trial Results
- 8.6.5. Estimated Sales Revenues
8.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
- 8.7.1. Therapy Overview
- 8.7.2. Clinical Trial Information
- 8.7.3. Clinical Trial Endpoints
- 8.7.4. Clinical Trial Results
- 8.7.5. Estimated Sales Revenues
8.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
- 8.8.1. Therapy Overview
- 8.8.2. Clinical Trial Information
- 8.8.3. Clinical Trial Endpoints
- 8.8.4. Clinical Trial Results
- 8.8.5. Estimated Sales Revenues
8.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
- 8.9.1. Therapy Overview
- 8.9.2. Clinical Trial Information
- 8.9.3. Clinical Trial Endpoints
8.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
- 8.10.1. Therapy Overview
- 8.10.2. Clinical Trial Information
- 8.10.3. Clinical Trial Endpoints
- 8.10.4. Clinical Trial Results
- 8.10.5. Estimated Sales Revenues
8.11. AUTO3 / CD19/22 CAR-T (Autolus)
- 8.11.1. Therapy Overview
- 8.11.2. Clinical Trial Information
- 8.11.3. Clinical Trial Endpoints
- 8.11.4. Clinical Trial Results
- 8.11.5. Estimated Sales Revenues

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. CAR-T Cell Therapies: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year of Partnership and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Most Popular Products: Analysis by Number of Partnerships
- 9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
- 9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
- 9.3.8. Analysis by Geography
  - 9.3.8.1. Intercontinental and Intracontinental Deals
  - 9.3.8.2. International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS

10.1. Chapter Overview
10.2. Types of Funding
10.3. CAR-T Cell Therapies: Funding and Investment Analysis
- 10.3.1. Analysis of Instances by Year
- 10.3.2. Analysis of Amount Invested by Year
- 10.3.3. Analysis by Type of Funding
- 10.3.4. Analysis by Type of Investor
- 10.3.5. Most Active Players: Analysis by Number of Instances
- 10.3.6. Most Active Investors: Analysis by Amount Invested
- 10.3.7. Analysis of Amount Invested by Geography
- 10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. CAR-T Cell Therapies: Patent Analysis
- 11.3.1. Analysis by Patent Publication Year
- 11.3.2. Analysis by Patent Application Year
- 11.3.3. Analysis by Geography
- 11.3.4. Analysis by Type of Player
- 11.3.5. Analysis by CPC Symbols
- 11.3.6. Analysis by Key Focus Area
- 11.3.7. Leading Players: Analysis by Number of Patents
- 11.3.8. CAR-T Cell Therapies: Patent Benchmarking
- 11.3.9. Analysis By Patent Characteristics
- 11.3.10. CAR-T Cell Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING

12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
- 12.3.1. Centralized Manufacturing Model
- 12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
- 12.4.1. Scale-Up
- 12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Key Considerations for Cell Therapy Manufacturing
- 12.7.1. Characterization
- 12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Process
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Players Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives

13. COST PRICE ANALYSIS

13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
- 13.3.1. Based on Associated Costs
- 13.3.2. Based on Availability of Competing Products
- 13.3.3. Based on Patient Segment
- 13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
- 13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global CAR-T Cell Therapies Market, 2022-2035
- 14.4.1. CAR-T Cell Therapies Market: Analysis by Target Indication
- 14.4.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
- 14.4.3. CAR-T Cell Therapies Market: Analysis by Key Players
- 14.4.4. CAR-T Cell Therapies Market: Analysis by Geography
- 14.4.5. Product Wise Sales Forecast
  - 14.4.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
    - 14.4.5.1.1. Sales Forecast (USD Million)
    - 14.4.5.1.2. Net Present Value
    - 14.4.5.1.3. Value Creation Analysis
  - 14.4.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
    - 14.4.5.2.1. Sales Forecast (USD Million)
    - 14.4.5.2.2. Net Present Value (USD Million)
    - 14.4.5.2.3. Value Creation Analysis
  - 14.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
    - 14.4.5.3.1. Sales Forecast (USD Million)
    - 14.4.5.3.2. Net Present Value (USD Million)
    - 14.4.5.3.3. Value Creation Analysis
  - 14.4.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
    - 14.4.5.4.1. Sales Forecast (USD Million)
    - 14.4.5.4.2. Net Present Value (USD Million)
    - 14.4.5.4.3. Value Creation Analysis
  - 14.4.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
    - 14.4.5.5.1. Sales Forecast (USD Million)
    - 14.4.5.5.2. Net Present Value (USD Million)
    - 14.4.5.5.3. Value Creation Analysis
  - 14.4.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
    - 14.4.5.6.1. Sales Forecast (USD Million)
    - 14.4.5.6.2. Net Present Value (USD Million)
    - 14.4.5.6.3. Value Creation Analysis
  - 14.4.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
    - 14.4.5.7.1. Sales Forecast (USD Million)
    - 14.4.5.7.2. Net Present Value (USD Million)
    - 14.4.5.7.3. Value Creation Analysis
  - 14.4.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
    - 14.4.5.8.1. Sales Forecast (USD Million)
    - 14.4.5.8.2. Net Present Value (USD Million)
    - 14.4.5.8.3. Value Creation Analysis
  - 14.4.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
    - 14.4.5.9.1. Sales Forecast (USD Million)
    - 14.4.5.9.2. Net Present Value (USD Million)
    - 14.4.5.9.3. Value Creation Analysis
  - 14.4.5.10. Descartes-11 (Cartesian Therapeutics)
    - 14.4.5.10.1. Sales Forecast (USD Million)
    - 14.4.5.10.2. Net Present Value (USD Million)
    - 14.4.5.10.3. Value Creation Analysis
  - 14.4.5.11. Descartes-08 (Cartesian Therapeutics)
    - 14.4.5.11.1. Sales Forecast (USD Million)
    - 14.4.5.11.2. Net Present Value (USD Million)
    - 14.4.5.11.3. Value Creation Analysis
  - 14.4.5.12. Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine)
    - 14.4.5.12.1. Sales Forecast (USD Million)
    - 14.4.5.12.2. Net Present Value (USD Million)
    - 14.4.5.12.3. Value Creation Analysis
  - 14.4.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
    - 14.4.5.13.1. Sales Forecast (USD Million)
    - 14.4.5.13.2. Net Present Value (USD Million)
    - 14.4.5.13.3. Value Creation Analysis
  - 14.4.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
    - 14.4.5.14.1. Sales Forecast (USD Million)
    - 14.4.5.14.2. Net Present Value (USD Million)
    - 14.4.5.14.3. Value Creation Analysis
  - 14.4.5.15. TAK-007 (Takeda)
    - 14.4.5.15.1. Sales Forecast (USD Million)
    - 14.4.5.15.2. Net Present Value (USD Million)
    - 14.4.5.15.3. Value Creation Analysis
  - 14.4.5.16. AUTO1 (Autolus)
    - 14.4.5.16.1. Sales Forecast (USD Million)
    - 14.4.5.16.2. Net Present Value (USD Million)
    - 14.4.5.16.3. Value Creation Analysis
  - 14.4.5.17. AUTO3 (Autolus)
    - 14.4.5.17.1. Sales Forecast (USD Million)
    - 14.4.5.17.2. Net Present Value (USD Million)
    - 14.4.5.17.3. Value Creation Analysis
  - 14.4.5.18. CD19 CAR-T (Bioray Laboratories)
    - 14.4.5.18.1. Sales Forecast (USD Million)
    - 14.4.5.18.2. Net Present Value (USD Million)
    - 14.4.5.18.3. Value Creation Analysis
  - 14.4.5.19. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
    - 14.4.5.19.1. Sales Forecast (USD Million)
    - 14.4.5.19.2. Net Present Value (USD Million)
    - 14.4.5.19.3. Value Creation Analysis
  - 14.4.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
    - 14.4.5.20.1. Sales Forecast (USD Million)
    - 14.4.5.20.2. Net Present Value (USD Million)
    - 14.4.5.20.3. Value Creation Analysis
  - 14.4.5.21. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
    - 14.4.5.21.1. Sales Forecast (USD Million)
    - 14.4.5.21.2. Net Present Value (USD Million)
    - 14.4.5.21.3. Value Creation Analysis
  - 14.4.5.22. BinD19 (Shenzhen BinDeBio)
    - 14.4.5.22.1. Sales Forecast (USD Million)
    - 14.4.5.22.2. Net Present Value (USD Million)
    - 14.4.5.22.3. Value Creation Analysis
  - 14.4.5.23. CARCIK-CD19 (CoImmune)
    - 14.4.5.23.1. Sales Forecast (USD Million)
    - 14.4.5.23.2. Net Present Value (USD Million)
    - 14.4.5.23.3. Value Creation Analysis
  - 14.4.5.24. PBCAR269A (Precision BioSciences / Servier)
    - 14.4.5.24.1. Sales Forecast (USD Million)
    - 14.4.5.24.2. Net Present Value (USD Million)
    - 14.4.5.24.3. Value Creation Analysis
  - 14.4.5.25. CD123 CAR-T cells Therapy (Chongqing Precision Biotechnology)
    - 14.4.5.25.1. Sales Forecast (USD Million)
    - 14.4.5.25.2. Net Present Value (USD Million)
    - 14.4.5.25.3. Value Creation Analysis
  - 14.4.5.26. BCMA CAR-T (Chongqing Precision Biotech)
    - 14.4.5.26.1. Sales Forecast (USD Million)
    - 14.4.5.26.2. Net Present Value (USD Million)
    - 14.4.5.26.3. Value Creation Analysis
  - 14.4.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
    - 14.4.5.27.1. Sales Forecast (USD Million)
    - 14.4.5.27.2. Net Present Value (USD Million)
    - 14.4.5.27.3. Value Creation Analysis
  - 14.4.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
    - 14.4.5.28.1. Sales Forecast (USD Million)
    - 14.4.5.28.2. Net Present Value (USD Million)
    - 14.4.5.28.3. Value Creation Analysis
  - 14.4.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
    - 14.4.5.29.1. Sales Forecast (USD Million)
    - 14.4.5.29.2. Net Present Value (USD Million)
    - 14.4.5.29.3. Value Creation Analysis
  - 14.4.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
    - 14.4.5.30.1. Sales Forecast (USD Million)
    - 14.4.5.30.2. Net Present Value (USD Million)
    - 14.4.5.30.3. Value Creation Analysis
  - 14.4.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
    - 14.4.5.31.1. Sales Forecast (USD Million)
    - 14.4.5.31.2. Net Present Value (USD Million)
    - 14.4.5.31.3. Value Creation Analysis
  - 14.4.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
    - 14.4.5.32.1. Sales Forecast (USD Million)
    - 14.4.5.32.2. Net Present Value (USD Million)
    - 14.4.5.32.3. Value Creation Analysis
  - 14.4.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
    - 14.4.5.33.1. Sales Forecast (USD Million)
    - 14.4.5.33.2. Net Present Value (USD Million)
    - 14.4.5.33.3. Value Creation Analysis
  - 14.4.5.34. CT053 (CARsgen Therapeutics)
    - 14.4.5.34.1. Sales Forecast (USD Million)
    - 14.4.5.34.2. Net Present Value (USD Million)
    - 14.4.5.34.3. Value Creation Analysis
  - 14.4.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
    - 14.4.5.35.1. Sales Forecast (USD Million)
    - 14.4.5.35.2. Net Present Value (USD Million)
    - 14.4.5.35.3. Value Creation Analysis
  - 14.4.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
    - 14.4.5.36.1. Sales Forecast (USD Million)
    - 14.4.5.36.2. Net Present Value (USD Million)
    - 14.4.5.36.3. Value Creation Analysis
  - 14.4.5.37. ALLO-605 (Allogene Therapeutics)
    - 14.4.5.37.1. Sales Forecast (USD Million)
    - 14.4.5.37.2. Net Present Value (USD Million)
    - 14.4.5.37.3. Value Creation Analysis
  - 14.4.5.38. WU CART 007 (Wugen)
    - 14.4.5.38.1. Sales Forecast (USD Million)
    - 14.4.5.38.2. Net Present Value (USD Million)
    - 14.4.5.38.3. Value Creation Analysis
  - 14.4.5.39. CT103A (Nanjing IASO Biotherapeutics)
    - 14.4.5.39.1. Sales Forecast (USD Million)
    - 14.4.5.39.2. Net Present Value (USD Million)
    - 14.4.5.39.3. Value Creation Analysis

15. PROMOTIONAL ANALYSIS

15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Kymriah®: Promotional Analysis
- 15.5.1. Drug Overview
- 15.5.2. Product Website Analysis
  - 15.5.2.1. Message for Healthcare Professionals
  - 15.5.2.2. Message for Patients
  - 15.5.2.3. Informative Downloads
- 15.5.3. Patient Support Services
15.6. Yescarta®: Promotional Analysis
- 15.6.1. Drug Overview
- 15.6.2. Product Website Analysis
  - 15.6.2.1. Message for Healthcare Professionals
  - 15.6.2.2. Message for Patients
  - 15.6.2.3. Informative Downloads
- 15.6.3. Patient Support Services
15.7. Tecartus®: Promotional Analysis
- 15.7.1. Drug Overview
- 15.7.2. Product Website Analysis
  - 15.7.2.1. Message for Healthcare Professionals
  - 15.7.2.2. Message for Patients
  - 15.7.2.3. Informative Downloads
- 15.7.3. Patient Support Services
15.8. Breyanzi®: Promotional Analysis
- 15.8.1. Drug Overview
- 15.8.2. Product Website Analysis
  - 15.8.2.1. Message for Healthcare Professionals
  - 15.8.2.2. Message for Patients
  - 15.8.2.3. Informative Downloads
- 15.8.3. Patient Support Services
15.9. Abecma®: Promotional Analysis
- 15.9.1. Drug Overview
- 15.9.2. Product Website Analysis
  - 15.9.2.1. Message for Healthcare Professionals
  - 15.9.2.2. Message for Patients
  - 15.9.2.3. Informative Downloads
- 15.9.3. Patient Support Services
15.10. Carvykti®: Promotional Analysis
- 15.10.1. Drug Overview
- 15.10.2. Product Website Analysis
  - 15.10.2.1. Message for Healthcare Professionals
  - 15.10.2.2. Message for Patients
  - 15.10.2.3. Informative Downloads
- 15.10.3. Patient Support Services

16. COMPANY PROFILES

16.1. Chapter Overview
16.2. Alaunos Therapeutics
16.3. Autolus
16.4. Bluebird Bio
16.5. Bristol Myers Squibb
16.6. Carsgen Therapeutics
16.7. Cellectis
16.8. Cellular Biomedicine Group
16.9. Gilead Sciences
16.10. Innovative Cellular Therapeutics
16.11. Kuur Therapeutics
16.12. Noile-Immune Biotech
16.13. Novartis
16.14. Shanghai GeneChem
16.15. Sinobioway Cell Therapy
16.16. Takara Bio
16.17. Wellington Zhaotai Therapies

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

18.1. Chapter Overview
18.2. Glycostem Therapeutics
- 18.2.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
18.2. Gracell Biotechnologies
- 18.2.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
18.3. TxCell
- 18.3.1. Interview Transcript: Miguel Forte, Chief Operating Officer
18.4. Kite Pharma
- 18.4.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.5. Celyad
- 18.5.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
18.6. Waisman Biomanufacturing
- 18.6.1. Interview Transcript: Brian Dattilo, Manager of Business Development
18.7. Theravectys
- 18.7.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development
18.8. Changhai Hospital
- 18.8.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
18.9. University of Colorado
- 18.9.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

CAR-T細胞療法市場 - 標的適応症別・標的抗原別・主要企業別・主要地域別：将来予測 (2022年～2035年)

CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2022-2035

目次

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 CAR-T細胞療法：市場情勢

第5章 重要な洞察

第6章 治験分析

第7章 主なオピニオンリーダー (KOL)

第8章 CAR-T細胞療法のプロファイル

第9章 事業提携・協力

第10章 資金提供・投資の分析

第11章 特許分析

第12章 ケーススタディ：細胞療法の製造

第13章 費用・価格分析

第14章 市場予測と機会分析

第15章 プロモーション分析

第16章 企業プロファイル

第17章 結論

第18章 企業役員の見解

第19章 付録1：表形式のデータ

第20章 付録2：企業・組織の一覧